Grundy S M, Vega G L
University of Texas Health Science Center, Center for Human Nutrition, Dallas 75235-9052.
Am J Med. 1987 Nov 27;83(5B):9-20. doi: 10.1016/0002-9343(87)90866-7.
The major effect of the fibrates on triglycerides is to promote triglyceride-rich lipoprotein catabolism through increased lipoprotein lipase activity. Fibrates also enhance lipolysis of plasma triglycerides by a means different from that of caloric restriction. Their effect on very low-density lipoprotein metabolism also differs from that of nicotinic acid. The effect of fibrate therapy upon low-density lipoprotein-cholesterol concentrations depends upon the patients' overall lipoprotein status. The responsible mechanisms are not understood. In hypertriglyceridemic patients, fibrates often reverse abnormal changes in low-density lipoprotein composition; low-density lipoprotein heterogeneity is reduced and small dense low-density lipoproteins are eliminated, apparently secondary to reduced levels of triglyceride-rich lipoproteins. Kinetic studies indicate that fibrates do not enhance low-density lipoprotein formation rates, thus contradicting the idea that fibrate therapy causes increased low-density lipoprotein cholesterol levels via increased conversion of very low-density lipoprotein to low-density lipoprotein. Though enhanced low-density lipoprotein catabolism in hypertriglyceridemia could occur via several mechanisms, the responsible factors are largely reversed by fibrate therapy. In non-hypertriglyceridemic patients, fibrates may actually enhance the fractional clearance of low-density lipoprotein and thus reduce low-density lipoprotein levels. Fibrate therapy reverses the typical high-density lipoprotein pattern of hypertriglyceridemic patients, producing more high-density lipoprotein2a and less high-density lipoprotein2b. Such treatment also increases high-density lipoprotein cholesterol levels in patients without definite hypertriglyceridemia. Synthesis rates of apolipoproteins AI and AII may be affected by fibrates. The fibrates' major effects on sterol metabolism are interference with cholesterol and bile acid synthesis and increased cholesterol secretion into bile. Although bile saturation increases in most patients, in only a relatively small percentage do gallstones actually develop; super-saturated bile is not sufficient to induce gallstone formation in most patients. Available data strongly imply that fibrates mobilized cholesterol out of tissue pools, perhaps by altering tissue cell membranes to allow cholesterol release from the cell surfaces.
贝特类药物对甘油三酯的主要作用是通过增加脂蛋白脂肪酶活性来促进富含甘油三酯的脂蛋白分解代谢。贝特类药物还通过一种不同于热量限制的方式增强血浆甘油三酯的脂解作用。它们对极低密度脂蛋白代谢的影响也与烟酸不同。贝特类药物治疗对低密度脂蛋白胆固醇浓度的影响取决于患者的整体脂蛋白状态。其相关机制尚不清楚。在高甘油三酯血症患者中,贝特类药物常常能逆转低密度脂蛋白组成的异常变化;低密度脂蛋白的异质性降低,小而密的低密度脂蛋白被清除,这显然是由于富含甘油三酯的脂蛋白水平降低所致。动力学研究表明,贝特类药物不会提高低密度脂蛋白的生成速率,因此与贝特类药物治疗通过增加极低密度脂蛋白向低密度脂蛋白的转化导致低密度脂蛋白胆固醇水平升高的观点相矛盾。虽然高甘油三酯血症中增强的低密度脂蛋白分解代谢可能通过多种机制发生,但相关因素在很大程度上可被贝特类药物治疗逆转。在非高甘油三酯血症患者中,贝特类药物实际上可能会增强低密度脂蛋白的部分清除率,从而降低低密度脂蛋白水平。贝特类药物治疗可逆转高甘油三酯血症患者典型的高密度脂蛋白模式,产生更多的高密度脂蛋白2a和更少的高密度脂蛋白2b。这种治疗还可提高无明确高甘油三酯血症患者的高密度脂蛋白胆固醇水平。载脂蛋白AI和AII的合成速率可能会受到贝特类药物的影响。贝特类药物对固醇代谢的主要作用是干扰胆固醇和胆汁酸的合成,并增加胆固醇向胆汁中的分泌。虽然大多数患者胆汁饱和度会升高,但只有相对较小比例的患者实际会形成胆结石;在大多数患者中,过饱和胆汁不足以诱发胆结石形成。现有数据强烈表明,贝特类药物可使胆固醇从组织池中动员出来,可能是通过改变组织细胞膜,使胆固醇从细胞表面释放。